
**THE ROLE OF THYROID HORMONES IN METABOLIC
REGULATION AND ENERGY EXPENDITURE**

Harsh Wardhan^{*1}, Abhijit Kumar Rai², Dr. Tanya Sharma³, Amit Kumar⁴

^{1,2}Student of B. Pharmacy at Mewar University, Gangrar, Chittorgarh (Rajasthan), 312901.

³HoD of College of Pharmacy at Mewar University, Gangrar, Chittorgarh (Rajasthan) 312901.

⁴Dean of College of Pharmacy at Mewar University, Gangrar, Chittorgarh (Rajasthan)
312901.

Article Received: 22 March 2026, Article Revised: 12 April 2026, Published on: 02 May 2026

***Corresponding Author: Harsh Wardhan**

Student of B. Pharmacy at Mewar University, Gangrar, Chittorgarh (Rajasthan), 312901.

DOI: <https://doi-doi.org/101555/ijarp.8351>

ABSTRACT:

The thyroid hormones (THs), comprising predominantly triiodothyronine(T3) and thyroxine(T4), are the main controllers of metabolic processes and energy homeostasis. Their action permeates the body and controls primitive metabolic rate, thermogenesis, lipid and carbohydrate metabolism, and mitochondrial function. This review outlines the physiological processes by which THs control metabolism, the molecular mechanisms involved, and the clinical applicability of thyroid dysfunction to metabolic health. In addition, we bandy recent developments in thyroid hormone analogues and their implicit remedial operations in metabolic diseases.

KEYWORDS: Thyroids, Thyroxine, Triiodothyronine, Thermogenesis, Hyperthyroidism, Homeostasis.

INTRODUCTION:


Thyroid hormones have a critical function in icing metabolic balance. They affect nearly every towel of the body, controlling a broad range of biochemical and physiological processes. The metabolic counteraccusations of thyroid dysfunction are immense, expressed in clinical countries of hypothyroidism, marked by weight gain and languor, and hyperthyroidism, generally presented with weight loss and enhanced expenditure of energy (1,2).

Synthesis and Regulation of Thyroid Hormones:

THs are produced in the thyroid gland by iodination of tyrosine remainders of thyroglobulin, catalysed by thyroid peroxidase. T4 is the major hormone buried, whereas T3, the biologically active form, is primarily produced through supplemental conversion by deiodinases (3,4). The HPT axis regulates TH homeostasis through feedback circles involving TRH and TSH (5).

Mechanisms of Action

T3 primarily acts by binding to nuclear thyroid hormone receptors (TRs), which affect the recap of genes. These receptors affect expression of genes, which are involved in mitochondrial function, oxidative phosphorylation, and substrate metabolism (6,7). Non-genomic conduct, which are intermediated by cytosolic or membrane- associated TRs, also play a part in the rapid-fire metabolic goods (8).



Thyroid Hormones and rudimentary Metabolic Rate

One of the characteristic conducts of THs is the control over rudimentary metabolic rate (BMR). T3 enhances oxygen uptake and heat product by stimulating mitochondrial biogenesis and uncoupling proteins (UCPs), primarily UCP1 in brown fat (9- 11). THs also raise Na/ K- ATPase exertion, farther accelerating energy expenditure (12).

Lipid Metabolism: THs spark lipolysis in adipose towel and liver adipose acid oxidation and drop serum cholesterol situations by converting the expression of LDL receptors and the product of corrosiveness acids (13- 15). Metabolic imbalance in TH situations may affect in hypercholesterolemia during hypothyroidism and lipid loss during hyperthyroidism (16).

Carbohydrate Metabolism: THs increase hepatic gluconeogenesis and glycogenolysis, enhance intestinal glucose immersion, and affect insulin perceptivity. While hyperthyroidism can beget glucose dogmatism, hypothyroidism tends to be accompanied by lesser insulin resistance (17- 19).

Mitochondrial Function and Thermogenesis: THs increase mitochondrial biogenesis, compound ATP product, and support adaptive thermogenesis. These functions are essential for energy balance and the adaption to changes in environmental temperature (20- 22).

Thyroid Dysfunction and Metabolic Disease: Thyroid dysfunction is an important contributor to metabolic runs. Hypothyroidism is associated with rotundity, dyslipidaemia, and non-alcoholic adipose liver complaint (NAFLD), whereas hyperthyroidism can worsen catabolic countries and sarcopenia (23- 25).

remedial operations Thyroid hormone analogs, including eprotirome and sobetirome, have been finagled to widely modulate metabolic pathways without cardiac side goods. These composites are promising for the treatment of dyslipidaemia and rotundity (26- 28).

CONCLUSION:

Thyroid hormones are core regulators of energy metabolism and expenditure. explication of their intricate mechanisms may give a lead to the discovery of targeted treatments for metabolic diseases. further work is demanded to more define treatment modalities and limit side goods.

REFERENCES

1. Brent GA. *N Engl J Med.* 2012; 367:155- 162.
2. Mullur R, et al. *Physio Rev.* 2014; 94:355- 382.
3. Bianco AC, et al. *Endocr Rev.* 2002; 23:38- 89.
4. Larsen PR. *Thyroid.* 2000; 10:417- 424.
5. Ortiga- Carvalho TM, et al. *Front Endocrinol (Lausanne).* 2016; 7:144.
6. Flamant F, et al. *Nat Rev Endocrinol.* 2017; 13:270- 280.
7. Cheng SY, et al. *Endocr Rev.* 2010; 31:139- 170.
8. Davis PJ, et al. *Steroids.* 2012; 77:1- 9.
9. Silva JE. *Thyroid.* 1995; 5:481- 492.
10. Cannon B, Nedergaard J. *Physiol Rev.* 2004; 84:277- 359.
11. Lopez M, et al. *Biochim Biophys Acta.* 2013; 1830:3957- 3963.
12. Oppenheimer JH, et al. *Science.* 1972; 176:285- 288.
13. Johansson L, et al. *Endocrinology.* 2005; 146:4786- 4792.
14. Duntas LH. *Nat Clin Pract Endocrinol Metab.* 2005; 1:242- 249.
15. Tan BK, et al. *J Clin Endocrinol Metab.* 2008; 93:3145- 3150.
16. Pearce EN, et al. *N Engl J Med.* 2013; 368:1237- 1244.
17. Dimitriadis G, et al. *Diabetologia.* 2006; 49:307- 317.
18. Maratou E, et al. *Endocrinology.* 2010; 151:503- 510.
19. Brenta G. *Thyroid.* 2011; 21:497- 509.
20. Weitzel JM, Iwen KA. *J Mol Endocrinol.* 2011; 47:R43- R51.
21. Cioffi F, et al. *Mol Cell Endocrinol.* 2013; 376:1- 11.
22. Wrutniak- Cabello C, et al. *Biochim Biophys Acta.* 2001; 150:41- 14.
23. Rezzonico J, et al. *Obes Surg.* 2008; 18:1389- 1393.
24. Biondi B, et al. *J Clin Endocrinol Metab.* 2005; 90:4884- 4890.
25. Nannipieri M, et al. *J Clin Endocrinol Metab.* 2009; 94:4726- 4733.
26. Trost SU, et al. *Rotation.* 2000; 102:2271- 2278.
27. Baxter JD, et al. *Curr Opin Investig medicines.* 2004; 5:834- 840.
28. Graeser AC, et al. *J Lipid Res.* 2009; 50:710- 716.